Deregulation of matriptase is a consistent feature of human epithelial cancers and correlates with poor disease outcome. We have previously shown that matriptase promotes multi-stage squamous cell carcinogenesis in transgenic mice through dual activation of pro-hepatocyte growth factor-cMet-Akt-mTor proliferation/survival signaling and PAR-2-Gαi-NFκB inflammatory signaling. Matriptase was congenitally and constitutively deregulated in our prior studies, and therefore it was unclear if aberrant matriptase signaling supports only initiation of tumor formation or if it is also critical for the progression of established tumors. To determine this, we here have generated triple-transgenic mice with constitutive deregulation of matriptase and simultaneous inducible expression of the cognate matriptase inhibitor, hepatocyte growth factor inhibitor (HAI)-2. As expected, constitutive expression of HAI-2 suppressed the formation of matriptase-dependent tumors in 7,12-Dimethylbenz(a)anthracene-treated mouse skin. Interestingly, however, the induction of HAI-2 expression in already established tumors markedly impaired malignant progression and caused regression of individual tumors. Tumor regression correlated with reduced accumulation of tumor-associated inflammatory cells, likely caused by diminished expression of pro-tumorigenic inflammatory cytokines. The data suggest that matriptase-dependent signaling may be a therapeutic target for both squamous cell carcinoma chemoprevention and for the treatment of established tumors.
INTRODUCTION
The membrane-anchored serine protease, matriptase, has gathered considerable attention in the context of human carcinogenesis, because it is deregulated with unusual high frequency in the epithelial compartment of human carcinomas of diverse origin, because its expression is negatively correlated with clinical outcome in several human carcinomas and certain hematopoietic malignancies, and because matriptase promotes tumorigenesis in several animal models. In regard to the latter, we have previously shown that low-level, constitutive expression of matriptase in the basal keratinocyte compartment of transgenic mice suffices to induce spontaneous ras-independent multi-stage squamous cell carcinogenesis and to potentiate ras-dependent malignant transformation induced by 7,12-Dimethylbenz(a) anthracene (DMBA). 22 Malignant transformation of squamous epithelium, including DMBA-induced transformation of mouse epidermis, is a sequential process that occurs through distinct stages that include hyperplasia, dysplasia, papilloma, carcinoma in situ, invasive carcinoma and metastatic disease. 23 The contribution of deregulated matriptase activity to early stage squamous cell carcinogenesis was established in our previous studies by the lack of any pre-malignant progression in bitransgenic mice that constitutively overexpress matriptase along with the cognate matriptase inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1). 22 However, whether the membraneanchored serine protease also supports late-stage progression of squamous cell carcinogenesis has not been determined. In this study, we therefore generated triple-transgenic mice with constitutive deregulation of matriptase and simultaneous inducible expression of the potent cognate matriptase inhibitor HAI-2, 19, 24, 25 specifically in matriptase overexpressing cells. This inducible expression of HAI-2 enabled the acute blunting of matriptase activity after epidermal tumors were established. Using this novel experimental setup, we now show that matriptase is a critical promoter of late stages of squamous cell carcinoma progression and induces pro-tumorigenic chemokine and cytokine release, and inflammatory cell accumulation in established tumors. Taken together, these data indicate that matriptase may be a suitable therapeutic target for both squamous cell carcinoma chemoprevention and for the treatment of established tumors.
RESULTS AND DISCUSSION
To determine the stage-specific contribution of matriptase to squamous cell carcinogenesis, we generated two novel transgenic mouse strains. The first strain constitutively expressed an hemagglutinin (HA) epitope-tagged murine Spint2 complementary DNA (cDNA; encoding HAI-2) under control of the bovine keratin-5 promoter, hereafter referred to as K5-Spint2 +/0 mice ( Figures 1a and b , data are shown for one established transgenic line used for all further experiments). Reverse transcriptase-PCR analysis of messenger RNA from skin extracts showed that K5-Spint2 mice displayed an increase in total Spint2 messenger RNA (Figure 1b , compare lanes 1 with 2-4 and 5-7). This resulted in a marked increase in total epidermal HAI-2, as determined by Western blot using mouse HAI-2 antibodies (Figure 1d , top panel, compare lanes 1 and 3). We next crossed K5-Spint2 +/0 mice with previously generated K5-St14 +/0 mice, expressing a murine matriptase (St14) cDNA under control of the bovine keratin-5 promoter, 22 to generate bi-transgenic K5-St14 +/0 ;K5-Spint2 +/0 mice and their single-transgenic and wildtype littermates (Figure 1c) . Western blot analysis showed that HAI-2 was well expressed in the bi-transgenic K5-St14 +/0 ;K5-Spint2 +/0 mice (Figure 1d , top panel, compare lanes 3 and 4). Likewise, Western blot analysis using a matriptase antibody that recognizes the C-terminal serine protease domain showed that the level of total and activated epidermal matriptase was unaffected by the level of expression of HAI-2 ( Figure 1e, top panel, compare lanes 1 with 3 and 2 with 4) . Finally, double immunofluorescence analysis using antibodies against the HA epitope tag of the transgenic HAI-2 fusion protein and antibodies against matriptase showed widespread colocalization of HAI-2 with matriptase in the basal keratinocyte compartment (compare Figure 1f with Figures 1g, i and j, examples with arrows in Figure 1k ).
To determine if constitutive HAI-2 expression impairs matriptase-dependent squamous cell carcinoma initiation, we next subjected the skin of cohorts of K5-St14 +/0 ;K5-Spint2
bi-transgenic mice and their associated K5-St14 +/0 , K5-Spint2
and wildtype littermates to topical treatment with DMBA and followed tumor formation by outward inspection for 30 weeks ( Figure 1l ). As previously reported, 22, 26, 27 DMBA treatment did not result in tumor formation in wildtype mice (Figure 1l, red lines) . 49 Bovine keratin-5 promoter (K5 promoter, yellow), rabbit β-globin exons (E, light blue), rabbit β-globin intron (red), mouse Spint2-HA cDNA (purple) and rabbit β-globin polyadenylation signal (PA, gray). Positions of primers used for mouse genotyping and reverse transcriptase-PCR (RT-PCR) analysis are indicated (arrows). The linearized transgene vector was microinjected into the male pronucleus of FVB/NJ zygotes, which then were implanted into pseudopregnant mice. Spint2 transgenic founders were identified by Southern-blot hybridization of NotI-digested genomic DNA using a 32 Plabeled 600 bp probe spanning the entire Spint2 cDNA. The Spint2 transgenic lines were maintained in the hemizygous state (K5-Spint2
) in an FVB/NJ background and were genotyped by PCR using genomic DNA from tail biopsies with the following primer pairs: 5′-ATATATGCGGCCGCGCCACCATGGCGCAGCTTTGTGAGCTG-3′ and 5′-ATATATGCGGCCGCTTAGGCATAGTCAGGCACGTCATAAGGATACAAGAC-3′. ;K5-Spint2 +/0 (lane 4) mice, as determined by reducing Western blot using anti-matriptase antibodies. Positions of matriptase zymogen and activated matriptase are shown. NS indicates non-specific band. Western blot of α-tubulin is shown in the bottom panel as loading control. Epidermal protein extracts were prepared by homogenizing the tissue in ice-cold lysis buffer (1% Triton X-100, 0.5% Sodium-deoxycholate in phosphate buffered saline (PBS) plus Proteinase Inhibitor Cocktail (Sigma, St Louis, MO, USA)) and incubated on ice for 10 min. The lysates were spun and the supernatant was mixed with 4 × SDS sample buffer (NuPAGE, Invitrogen, Carlsbad, CA, USA) containing 7% β-mercaptoethanol and boiled for 10 min. The proteins were separated on a 4-12% BisTris NuPage gel and transferred to a 0.2-μm pore size PVDF membrane (Invitrogen). The membrane was blocked with 5% nonfat dry milk in tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) for 1 h at room temperature. The membrane was probed with anti-matriptase antibody (AF3946, R&D Systems) diluted in 1% nonfat dry milk in TBS-T overnight at 4°C. The next day, the membrane was washed three times for 5 min each in TBS-T and incubated for 1 h with alkaline phosphatase-conjugated secondary antibodies (Thermo Scientific, Waltham, MA, USA). After three 5-min washes with TBS-T, the signal was developed using nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate solution (Pierce, Thermo Scientific, Rockford, IL, USA). ;K5-Spint2 +/0 (i-k) skin samples were analyzed by immunofluorescence using antibodies against matriptase (f, i) and HA-tag for HAI-2 (g, j). Matriptase and HAI-2 expression co-localize in cells of the basal layer of the epidermis (merge, h, k, arrows in k). Skin samples from mice were fixed in 4% paraformaldehyde in PBS for 24 h, embedded into paraffin and sectioned. Tissue sections were cleared with xylene substitute, rehydrated in a graded series of alcohols and boiled in Reduced pH Retrieval Buffer (Bethyl, Montgomery, TX, USA) for 20 min for antigen retrieval. The sections were blocked for 1 h in PBS containing 10% horse serum and incubated at 4°C overnight with sheep-anti-matriptase (AF3946, R&D Systems) and rabbit-anti-HA (H6908, Sigma) for detection of transgenic HAI-2. The slides were washed three times for 5 min with 3% BSA in PBS and 0.1% Triton X-100 and incubated at room temperature for 1 h with Alexa fluor 594-labeled donkey anti-sheep and FITC-labeled goat-anti-rabbit antibodies (Zymed, Invitrogen). Tissue sections then were washed three times for 5 min with PBS and mounted with VectaShield Hard set Mounting Medium (Vector Laboratories Inc., Burlingame, CA, USA). The samples were subjected to laser scanning confocal microscopy using the Leica TCS SP2 system (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA) and Zeiss LS700 system (Carl Zeiss Microscopy, LLC). (l) Kaplan-Meier analysis of tumor-free survival of littermate K5-St14
K5-Spint2
+/0 (n = 12, green), K5-St14 +/0 (n = 11, blue), K5-Spint2 +/0 (n = 9, purple) and wildtype (n = 8, red) mice. The mice received five treatments of 250 μg/ml DMBA in acetone every 3 weeks. The mice were monitored for up to 30 weeks for tumor formation. Po0.0001, K5-St14 +/0 versus other genotypes (log-rank test, two-tailed). The experiments were performed in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited vivarium following Institutional Guidelines and standard operating procedures. (m, n) Representative hematoxylin and eosin stained sections of squamous cell carcinoma at low and high (insets) magnification in K5-St14 +/0 (m) and K5-St14
;K5-Spint2 +/0 (n) transgenic mice 6 weeks after initiation of DMBA treatment. The histological appearance of tumors is similar irrespective of genotype. Size bars = 100 μm. Skin and tumor tissues were fixed for 24 h in 4% paraformaldehyde in phosphate buffered saline, processed into paraffin, sectioned into sagittal 3-μm sections and stained with hematoxylin and eosin prior to histopathological assessment. (o-t) K5-St14 +/0 (o-q) and K5-St14 +/0 ;K5-Spint2 +/0 (r-t) squamous cell carcinoma samples were analyzed by immunofluorescence using antibodies against matriptase (o, r) and the HA-tag for HAI-2 (p, s). Matriptase and HAI-2 expression co-localize in tumor cells throughout the malignant tumor (merge, q, t, examples with arrows in q). Size bars = 50 μm. Immunofluorescence was performed as described above.
In sharp contrast, all mice overexpressing matriptase in basal keratinocytes developed tumors within 7 weeks of treatment ( Figure 1l , blue lines) in agreement with previous studies. 22 As described previously for HAI-1, 22 3, 5 and 7) . HAI-2 is efficiently induced only in cells containing rtTa2S-M2 (constitutively expressing the tetracycline transactivator (rtTA)) and pBig-Spint2-HA plasmids. HEK293 cells were grown in Dulbecco's modified Eagles medium (DMEM) supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, Life Technologies, Grand Island, NY, USA) at 37°C in an atmosphere of 5% CO 2 . HEK293 cells were transfected using Turbofect (Thermo Scientific) according to the manufacturer's instructions, and then were treated with doxycycline for 48 h or left untreated. Western blot analysis was performed as described in Figure 1 ;pBig-HAI-2 +/0 triple-transgenic mice were topically treated with 250 μg/ml of DMBA every 3 weeks. Once tumors were outwardly visible, the mice were randomized into two groups that were fed either doxycycline-containing chow (n = 6) to induce HAI-2 expression in K5-expressing cells or were fed control chow (n = 6) and observed for an To investigate the role of matriptase in the later stages of squamous cell carcinoma progression, we next generated a second transgenic mouse line in which matriptase is constitutively expressed under the control of the Keratin-5 promoter and in which HAI-2 was also expressed in a Keratin-5 promoterdependent, but in an inducible, manner. For this purpose, we first generated a transgenic mouse strain in which the HA-tagged Spint2 cDNA was expressed under the control of a tetracyclineinducible promoter (Figure 2a , herafter pBig-Spint2 +/0 mice). Studies in HEK293 cells confirmed that HAI-2 expression from this promoter was efficiently induced by the tetracycline analog, doxycycline, specifically in cells expressing a tetracycline transactivator protein consisting of the E. coli tetracycline repressor fused to the Herpes Simplex Virus VP16 transactivation domain 28 ( Figure 2b ). Southern blot using genomic DNA from wildtype and transgenic mice showed a successfully inserted fragment compatible in size with the Spint2 cDNA ( Figure 1c, lane  2) . Consistent with this, when the pBig-Spint2 +/0 mice were crossed to previously generated K5TetOn +/0 mice expressing the tetracycline transactivator protein under the control of the bovine keratin-5 promoter, 29 HAI-2 expression could be specifically induced in the basal keratinocyte compartment by administration of doxycycline-containing chow to the ensuing pBig-Spint2 +/0 ; K5TetOn +/0 bi-transgenic mice ( Figure 2d , examples with arrowheads in right panel).
The pBig-Spint2 +/0 ;K5TetOn +/0 bi-transgenic mice next were crossed to K5-St14 +/0 mice to generate triple-transgenic pBigSpint2 +/0 ;K5TetOn +/0 ;K5-St14 +/0 mice. The mice were then subjected to DMBA treatment as described above to induce skin tumor formation (Figure 3a) . Once tumors emerged, the mice were randomly assigned to two groups. The first group continued to feed on normal chow, whereas the second group was fed doxycycline-containing chow to induce HAI-2 expression. Both treatment groups were then followed for an additional 14 weeks, and the change in tumor multiplicity and total tumor burden was then enumerated (Figures 3b and e) . As expected, a prolific progression of tumors was observed in mice fed with normal chow. The median increase in tumor multiplicity was 6.5 and the median increase in total tumor burden was 0.4 g (Figures 3d and e, golden squares). As also expected, all tumors visible at study initiation increased in size (examples with arrows in Figures 3b and  b′) . Interestingly, however, tumor progression in mice fed with doxycycline-containing chow was markedly blunted, with an increase in median tumor multiplicity of just 1 and an increase in median total tumor burden of just 0.05 g (Figures 3d and e, red  squares) . Furthermore, tumors visible at study initiation often displayed obvious regression, indicative of a specific requirement of matriptase activity for continued tumor growth (examples with arrowheads in Figures 3c and c′) . Immunofluorescence analysis of tumors from doxycycline-fed and control mice using antibodies against the HA epitope tag of the HAI-2 fusion protein and antibodies against matriptase showed induction of HAI-2 expression by doxycycline and frequent co-localization of HAI-2 with matriptase in tumor cells (Figures 1f and k, compare Figure 1f with Figure 1i and Figure 1g with Figure 1j ). HAI-2 expression, however, was generally patchy, with some areas of the tumors showing intense staining (Figure 3i , arrowheads) and other areas being devoid of staining. This non-homogeneous induction of HAI-2 provides a likely explanation for the relatively unimpeded growth of some tumor nodules and the occasional emergence of new tumors during doxycycline administration.
To mechanistically dissect how matriptase promotes the progression of established tumors, we performed a comparative histological analysis of tumor lesions and adjacent hyperplastic tissue of mice fed normal or doxycycline-containing chow (Figures  4a and p) . No significant effect of HAI-2 induction was observed on tumor cell proliferation (Figure 4m . Densities of macrophages, neutrophils and T lymphocytes were significantly increased in tumors from mice that were fed with normal chow when compared with those that were fed with doxycycline-containing chow to induce HAI-2 expression. *P o0.0198 and **P o0.0097 in n, **P o0.0016 and ***P o0.0001 in o, *P o0.0163 and **P o0.0048 in p, SCC fed control chow versus other groups (unpaired Student's t-test, two-tailed). Skin and tumor tissues were fixed for 24 h in 4% paraformaldehyde in phosphate buffered saline, processed into paraffin and cut into sagittal 3-μm sections. Immunohistochemistry was performed using the following primary antibodies, anti-Ki-67 (Dako, Carpinteria, CA, USA), anti-Mac1 [Cd11b] (Abcam, Cambridge, MA, USA), anti-Myeloperoxidase (Abcam) and anti-CD3 (Abcam). After incubation with secondary antibodies, slides were developed using the diaminobenzidine substrate (Sigma-Aldrich, St Louis, MO, USA), mounted and scanned using Scanscope (Leica, Carl Zeiss Microscopy, LLC). (q-s) RNA was isolated from the epidermis of 1-day-old wildtype (brown squares, n = 7), K5-St14 +/0 (blue squares, n = 9), K5-Spint2 +/0 (green squares, n = 7) and K5-St14 +/0 ;K5-Spint2 +/0 (purple squares, n = 5) mice. Quantification of Cxcl1 (q), Tslp (r) and Csf2 (s) messenger RNA (mRNA) levels were performed by real-time PCR using TaqMan probes. Cxcl1, Tslp and Csf2 mRNA were all increased in the K5-St14 +/ 0 mice when compared with K5-St14 +/0 ;K5-Spint2
; K5-Spint2 +/0 and wildtype littermates. **P o0.0025 in q, P = NS in r, *P = 0.0274 and P = NS in s, K5-St14 +/0 versus the other genotypes (Mann-Whitney U-test, two-tailed). Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), as recommended by the manufacturer. Cxcl1, Tslp and Csf2 qPCRs were done using TaqMan probes following the manufacturer's instructions (Life Technologies).
littermates (Figures 4q and s) . We chose to analyze the three chemokine/cytokine genes because they were previously shown to be induced by matriptase in skin tumors, 26 and we chose newborn mice because the skin is histologically normal at birth 22 and differences in cytokine expression, therefore, are more likely to be a direct consequence of matriptase-mediated inflammatory signaling. All three cytokine or chemokine genes displayed markedly increased expression in K5-St14 +/0 mice as compared to wildtype littermates, although significance only was obtained for Cxcl1 (Figures 4q and s, blue squares, compare with brown squares). Interestingly, however, this matriptase-mediated increase in inflammatory cytokine expression was abrogated by simultaneous HAI-2 expression (Figures 4q and s , compare purple squares to brown and blue squares). Taken together, these data suggest that matriptase promotes the progression of established epidermal tumors at least in part through induction of pro-tumorigenic inflammatory cytokines.
Trypsin-like serine proteases with their extracellular location and well-known mechanism of catalysis and zymogen activation are long-established as excellent drug targets. 30 The capacity of genetic downregulation of matriptase activity to induce stasis or regression of established tumors that we demonstrated in this study uncovers a critical contribution of the protease also to late stages of squamous cell carcinoma progression, and illustrates the potential utility of its pharmacological targeting for both squamous cell carcinoma chemoprevention and treatment of established tumors. Thus, even epidermal tumors in which ras is activated by topical DMBA application 22, [31] [32] [33] [34] remained dependent on matriptase proteolytic activity for further expansion and often regressed in its absence. The exact cellular mechanism by which this tumor regression occurred remains to be established. We did not observe obvious differences in tumor cell proliferation, apoptosis (data not shown) or necrosis (data not shown), although it is conceivable that the histological procedures used to assess these parameters may not be sufficiently sensitive to detect subtle changes. Alternatively, tumor regression may be a rapid process that is not captured in the collected tumor samples. We previously identified two matriptase-dependent signaling pathways that each is essential for initiating malignant transformation of squamous epithelium: (a) A cMet-Akt-mTor proliferation/survival signaling pathway, initiated by matriptase cleavage of keratinocyte cell surface-bound pro-hepatocyte growth factor, and (b) a Gαi-NFκB inflammatory signaling pathway, initiated by matriptase cleavage of keratinocyte protease-activated receptor-2. 26, 27 The marked reduction in the abundance of tumor-associated inflammatory cells observed after matriptase inhibition in established tumors would suggest that protease-activated receptor-2-dependent pro-inflammatory signaling represents at least one molecular component of matriptase promotion of late-stage carcinogenesis. However, matriptase also has been proposed to promote progression of other cancers through the activation of pro-macrophage-stimulating protein 1/pro-hepatocyte-like growth factor, 35 receptor bound pro-urokinase plasminogen activator, [36] [37] [38] src-associated transmembrane protein SIMA135/ CDCP1/TRASK 39 and platelet-derived growth factor-D. 40 A considerable number of small molecule and macromolecular inhibitors of matriptase have been developed. [41] [42] [43] [44] [45] [46] [47] [48] The data presented in this paper should further stimulate ongoing efforts toward the development and use of inhibitors of matriptase for human cancer treatment.
